About Processa

Processa Pharmaceuticals (OTCMKTS: PCSA) was formed in October 2017 as a result of an asset acquisition of Promet Therapeutics, LLC by Heatwurx, Inc (OTCMKTS: HUWX). Processa's mission is to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The company is headquartered in Hanover, Maryland.

To advance its mission, Processa has assembled an unparalleled Management Team, Board of Directors and Product Development Team. The Processa Team are experts in developing drug products from IND enabling studies to NDA submission. The company's combined scientific, development and regulatory experience has resulted in more than 30 drug approvals by the U.S. Food and Drug Administration (FDA) and more than 100 meetings with the FDA while working on more than 50 drug development programs, including drug products targeted to orphan disease and unmet medical need conditions.

Processa's plan is to have a pipeline of drugs which already have some proof-of-concept clinical data supporting its clinical use in the indication selected and in 2-4 years after acquisition will either:

  1. Have completed the pivotal study or
  2. be ready for a pivotal study and out-licensing.

The Company is also actively seeking assets to complete its pipeline of products and fulfill its mission to help patients who have no treatment options or need better treatment options.

Processa's lead product, PCS499, will be investigated for the treatment of Necrobiosis Lipoidica, a necrotizing skin condition, caused by several pathophysiological changes. A second unmet medical need under investigation is the use of PCS499 to treat radiation-related adverse effects in head & neck cancer. For both indications there is no FDA approved treatments and the present standard of care is not adequate for the patients.